ReviewTrends in cardiovascular medicine2019
Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.
Review in Trends in cardiovascular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Determinants of Abnormal Pulmonary Vasodilatory Response With Exercise in HFpEF: Pulmonary Vascular-Left Atrial Axis Abnormalities.Comprehensive Physiology · 2026Article
- Oxylipins are Associated With Poor Right Ventricular to Pulmonary Artery Coupling and Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.The American journal of cardiology · 2025Article
- Pulmonary gas exchange in relation to exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction.The European respiratory journal · 2025Article
- Evaluation of left atrial function and the relationship between left atrial stiffness index and exercise capacity in hypertension-related heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2024Article
- Omics and Extreme Phenotyping Reveal Longitudinal Association Between Left Atrial Size and Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension.Journal of the American Heart Association · 2023Article
- The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal.Reviews in cardiovascular medicine · 2023Review
- Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.Frontiers in cardiovascular medicine · 2023Article
- Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension.American heart journal plus : cardiology research and practice · 2022Article
- Levosimendan-induced venodilation is mediated by opening of potassium channels.ESC heart failure · 2021Review
- Endogenous Hemoprotein-Dependent Signaling Pathways of Nitric Oxide and Nitrite.Inorganic chemistry · 2021Review
- Impaired pulmonary vasomotor control in exercising swine with multiple comorbidities.Basic research in cardiology · 2021Article
- The different facets of sickle cell disease-related pulmonary hypertension.Current opinion in pulmonary medicine · 2021Review
- Article
- Cellular and molecular pathobiology of heart failure with preserved ejection fraction.Nature reviews. Cardiology · 2021Review
- Intracavitary Electrocardiogram Guidance Aids Excavation of Rhythm Abnormalities in Patients with Occult Heart Disease.Journal of healthcare engineering · 2021Article
- Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction.Frontiers in pharmacology · 2021Review
- Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.Heart (British Cardiac Society) · 2020Review
- Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease.Frontiers in medicine · 2020Review
- Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.The Journal of physiology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) is defined as clinical features of heart failure, ideally with biomarker evidence such as elevated plasma natriuretic peptide levels, in the setting of an ejection fraction (EF) greater than 50% and imaging evidence of diastolic left ventricular dysfunction [1,2]. In the absence of cardiac imaging or invasive hemodynamics, this is a clinical syndrome that is often indistinguishable from heart failure with reduced ejection fraction (HFrEF). HFpEF and HFrEF present with a cadre of comparable signs and symptoms including jugular venous distention, pulmonary rales on auscultation, breathlessness, orthopnea, exercise intolerance, exertional dyspnea, fatigue and peripheral edema. HFpEF accounts for at least half of all diagnoses of heart failure [1,2]. Pulmonary hypertension (PH) is a common complication of HFpEF that is linked to worse disease morbidity and mortality. In fact, mortality has been linked to increases in the intrinsic pulmonary vascular resistance in the setting of increased left ventricular end diastolic pressure, characterized hemodynamically by rises in the transpulmonary pressure gradient, pulmonary vascular resistance or diastolic pressure gradient. Despite being the most common form of PH, there are no approved therapies for the treatment of PH secondary to HFpEF. This review will summarize the hemodynamic classifications of PH in the setting of HFpEF, mechanisms of disease, the potential contribution of pulmonary vascular disease to poor outcomes in patients with HFpEF, and new approaches to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.